Α gemcitabine plus 5-fluorouracil combination inhibits gastric-cancer liver metastasis in a PDOX model: A novel treatment strategy

Norihiko Sugisawa, Hiroto Nishino, Takashi Higuchi, Jun H.O. Park, Jun Yamamoto, Yoshihiko Tashiro, Kei Kawaguchi, Michael Bouvet, Michiaki Unno, Robert M. Hoffman

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aim: We established a new patient-derived orthotopic xenograft (PDOX) model of gastric cancer liver metastasis and evaluated the efficacy of a novel combination chemotherapy, gemcitabine (GEM) plus 5-fluorouracil (5-FU), compared to a standard regimen of oxaliplatinum (L-OHP) plus 5-FU on the liver metastasis. Materials and Methods: Patient-derived gastric cancer was established in nude mice from the patient’s surgical tumor specimen. A single tumor fragment was implanted in the liver of nude mice. The mice with tumors were treated by GEM plus 5-FU or L-OHP plus 5-FU. Results: GEM plus 5-FU or L-OHP plus 5-FU significantly and similarly inhibited tumor growth on the liver compared to the untreated control (p=0.007, p=0.02, respectively). Conclusion: GEM plus 5-FU could be a novel future clinical alternative to L-OHP plus 5-FU in gastric cancer patients who cannot tolerate platinum drugs.

Original languageEnglish
Pages (from-to)5393-5397
Number of pages5
JournalAnticancer research
Volume40
Issue number10
DOIs
Publication statusPublished - 2020 Oct

Keywords

  • 5-fluorouracil
  • Gastric cancer
  • Gemcitabine
  • Liver metastasis
  • Nude mice
  • Oxaliplatinum
  • Patient-derived orthotopic xenograft (PDOX)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Α gemcitabine plus 5-fluorouracil combination inhibits gastric-cancer liver metastasis in a PDOX model: A novel treatment strategy'. Together they form a unique fingerprint.

Cite this